| Is SIGA Still Worth the Wait? VFC submits: Shares of SIGA Technologies have approached the eight dollar level of late, rebounding nicely from the low of under five dollars about six months ago. The SIGA stock reached a high of over ten bucks last December in anticipation of a possible awarding of a BARDA contract for the ST-246 smallpox vaccine. The contract did not pan out at the time, although some modifications to the application process in the interest of creating competition were announced around that time.A $2.8 million contract was awarded to Siga by the Department of Defense in early March, although this one was for ST-669, a broad-spectrum anti-viral. Complete Story » seekingalpha.com |
Glaxo Rival Paid Fees to Doctor Who Voted Against Avandia A doctor who voted against the diabetes drug Avandia at an FDA advisory panel last week said he earlier served a paid speaker for the maker of a rival drug. online.wsj.com |
NPS Pharmaceuticals, Inc. Q2 2010 Earnings Conference Call Transcript NPS Pharmaceuticals, Inc. Q2 2010 Earnings Conference Call August 4, 2010 17:00 E.TComplete Story » seekingalpha.com |
Novartis Unit to Pay $422.5 Million in Marketing Case A U.S. subsidiary of Novartis has agreed to pay $422.5 million to resolve criminal and civil charges that it illegally marketed the epilepsy drug Trileptal and paid kickbacks to doctors. online.wsj.com |
PPD Appoints Andreas Tschirky as Leader of BioDuro [Business Wire] - PPD, Inc. today announced it has appointed Andreas Tschirky, Ph.D., as leader of BioDuro. In this role, Dr. Tschirky will have responsibility for providing scientific and operational leadership and managing the growth of the Beijing-based drug discovery services company PPD acquired last year. us.rd.yahoo.com |